Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leopold Sellner

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Frontiers in Immunology|January 30, 2018
Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia PatientsJean-Marc Hoffmann, Maria-Luisa Schubert, Lei Wang, et al.
Cancers|January 11, 2022
Intracellular Amplifiers of Reactive Oxygen Species Affecting Mitochondria as RadiosensitizersHong-Gui Xu, Viktor Reshetnikov, Marit Wondrak, et al.
BMJ Open|May 22, 2019
Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocolMaria-Luisa Schubert, Anita Schmitt, Leopold Sellner, et al.
Blood Cancer Discovery|April 17, 2026
A Phase 2, Open-Label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non-Hodgkin LymphomaJustin M Darrah, Indumathy Varadarajan, Amitkumar Mehta, et al.
Journal of Medicinal Chemistry|January 31, 2015
Improved synthesis of N-benzylaminoferrocene-based prodrugs and evaluation of their toxicity and antileukemic activitySteffen Daum, Vasiliy F Chekhun, Igor N Todor, et al.
Frontiers in Immunology|December 28, 2020
Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T CellsMingya Yang, Lei Wang, Ming Ni, et al.
Frontiers in Immunology|June 14, 2021
Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell ImmunotherapyMingya Yang, Lei Wang, Ming Ni, et al.
Leukemia|February 2, 2021
EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4<sup>+</sup> T cells in chronic lymphocytic leukemiaPhilipp M Roessner, Laura Llaó Cid, Ekaterina Lupar, et al.
Bioinformatics (Oxford, England)|February 8, 2017
ARResT/Interrogate: an interactive immunoprofiler for IG/TR NGS dataVojtech Bystry, Tomas Reigl, Adam Krejci, et al.
British Journal of Haematology|September 17, 2013
Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemiaAlexander Jethwa, Jennifer Hüllein, Tatjana Stolz, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Frontiers in Immunology|January 30, 2018
Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia PatientsJean-Marc Hoffmann, Maria-Luisa Schubert, Lei Wang, et al.
Cancers|January 11, 2022
Intracellular Amplifiers of Reactive Oxygen Species Affecting Mitochondria as RadiosensitizersHong-Gui Xu, Viktor Reshetnikov, Marit Wondrak, et al.
BMJ Open|May 22, 2019
Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocolMaria-Luisa Schubert, Anita Schmitt, Leopold Sellner, et al.
Blood Cancer Discovery|April 17, 2026
A Phase 2, Open-Label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non-Hodgkin LymphomaJustin M Darrah, Indumathy Varadarajan, Amitkumar Mehta, et al.
Journal of Medicinal Chemistry|January 31, 2015
Improved synthesis of N-benzylaminoferrocene-based prodrugs and evaluation of their toxicity and antileukemic activitySteffen Daum, Vasiliy F Chekhun, Igor N Todor, et al.
Frontiers in Immunology|December 28, 2020
Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T CellsMingya Yang, Lei Wang, Ming Ni, et al.
Frontiers in Immunology|June 14, 2021
Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell ImmunotherapyMingya Yang, Lei Wang, Ming Ni, et al.
Leukemia|February 2, 2021
EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4<sup>+</sup> T cells in chronic lymphocytic leukemiaPhilipp M Roessner, Laura Llaó Cid, Ekaterina Lupar, et al.
Bioinformatics (Oxford, England)|February 8, 2017
ARResT/Interrogate: an interactive immunoprofiler for IG/TR NGS dataVojtech Bystry, Tomas Reigl, Adam Krejci, et al.
British Journal of Haematology|September 17, 2013
Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemiaAlexander Jethwa, Jennifer Hüllein, Tatjana Stolz, et al.
Pageof 5